Goldman Sachs
VMD icon

Goldman Sachs’s Viemed Healthcare VMD Stock Holding History

Goldman Sachs’s Portfolio VMD Stock Details VMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9M Sell
1,222,534
-199,100
-14% -$1.97M ﹤0.01% 2972
2026
Q1 		$13.1M Sell
1,421,634
-25,399
-2% -$211K ﹤0.01% 2832
2025
Q4 		$10.8M Buy
1,447,033
+49,962
+4% +$342K ﹤0.01% 3030
2025
Q3 		$9.49M Buy
1,397,071
+639,151
+84% +$4.33M ﹤0.01% 3020
2025
Q2 		$5.24M Buy
757,920
+4,578
+0.6% +$31.1K ﹤0.01% 3365
2025
Q1 		$5.48M Sell
753,342
-4,231
-0.6% -$33.2K ﹤0.01% 3259
2024
Q4 		$6.08M Buy
757,573
+11,037
+1% +$95.8K ﹤0.01% 3255
2024
Q3 		$5.47M Buy
746,536
+19,925
+3% +$142K ﹤0.01% 3261
2024
Q2 		$4.76M Buy
726,611
+111,158
+18% +$838K ﹤0.01% 3197
2024
Q1 		$5.8M Buy
615,453
+364,175
+145% +$3.12M ﹤0.01% 2957
2023
Q4 		$1.97M Buy
251,278
+5,929
+2% +$43K ﹤0.01% 3939
2023
Q3 		$1.65M Buy
245,349
+5,265
+2% +$43.1K ﹤0.01% 3915
2023
Q2 		$2.35M Sell
240,084
-63,257
-21% -$642K ﹤0.01% 3748
2023
Q1 		$2.93M Buy
303,341
+110,116
+57% +$960K ﹤0.01% 3545
2022
Q4 		$1.46M Buy
193,225
+6,781
+4% +$45.9K ﹤0.01% 4162
2022
Q3 		$1.12M Sell
186,444
-118,291
-39% -$759K ﹤0.01% 4422
2022
Q2 		$1.64M Sell
304,735
-520,780
-63% -$2.81M ﹤0.01% 4214
2022
Q1 		$4.11M Sell
825,515
-64,956
-7% -$302K ﹤0.01% 3529
2021
Q4 		$4.65M Sell
890,471
-59,859
-6% -$334K ﹤0.01% 3484
2021
Q3 		$5.27M Sell
950,330
-161,685
-15% -$1.05M ﹤0.01% 3319
2021
Q2 		$7.95M Buy
1,112,015
+104,442
+10% +$905K ﹤0.01% 2910
2021
Q1 		$10.2M Sell
1,007,573
-66,650
-6% -$627K ﹤0.01% 2549
2020
Q4 		$8.34M Buy
1,074,223
+266,429
+33% +$2.34M ﹤0.01% 2611
2020
Q3 		$6.98M Buy
807,794
+167,672
+26% +$1.69M ﹤0.01% 2633
2020
Q2 		$6.14M Buy
640,122
+66,214
+12% +$515K ﹤0.01% 2643
2020
Q1 		$2.73M Buy
573,908
+329,965
+135% +$1.64M ﹤0.01% 3087
2019
Q4 		$1.51M Buy
243,943
+19,411
+9% +$135K ﹤0.01% 3852
2019
Q3 		$1.55M Buy
+224,532
New +$1.5M ﹤0.01% 3714

Other funds holding VMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Forager Capital Management Birmingham, Alabama $266M AUM 40% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Goldman Sachs's VMD Position: Q2 2026 in Review

Goldman Sachs reduced its Viemed Healthcare (VMD) stake by 14% in Q2 2026, selling an estimated $1.97M and leaving 1,222,534 shares worth $13.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2972.

Goldman Sachs first reported a position in VMD in Q3 2019 and has held it in 28 quarters since. 166 funds tracked by Wall St. Rank hold VMD as of Q2 2026.

  • Goldman Sachs held 1,222,534 shares of Viemed Healthcare worth $13.9M as of Q2 2026.
  • Goldman Sachs sold 199,100 Viemed Healthcare shares in Q2 2026, an estimated $1.97M.
  • Viemed Healthcare made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2972 holding.
  • Goldman Sachs first reported a position in Viemed Healthcare in Q3 2019 and has held it in 28 quarters since.
  • 166 funds tracked by Wall St. Rank held Viemed Healthcare as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.